Birdwatch Archive

Birdwatch Note

2024-03-18 11:16:05 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

この総説は下記に紹介されているようにmRNAワクチンの頻回接種後のIgG4の上昇で「免疫寛容」が促進される「かも」といっているだけで↓ https://www.igakuken.or.jp/r-info/covid-19-info182.html 「免疫寛容」の有無に関わらず、実際にはワクチンの発症・重症予防効果は際限なく繰り返し報告済な事に注意が必要です。 ワクチンの頻回接種のオミクロンへの発症予防効果は遅れて行われた幼児のランダム化比較試験でも確認されており↓ https://www.cov19-vaccine.mhlw.go.jp/qa/uploads/0150_221025.pdf オミクロン期の頻回接種の発症・重症予防効果は観察研究のメタ解析でも示され↓ https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00409-1/fulltext 国内でもオミクロン期でも感染研から示され https://medical-tribune.co.jp/news/2023/0519556650/ 長崎大からも示されています https://www3.nhk.or.jp/news/html/20230304/k10013998631000.html

Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1769660789219262871

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1769684194702381379
  • noteId - 1769684194702381379
  • participantId -
  • noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
  • createdAtMillis - 1710760565817
  • tweetId - 1769660789219262871
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 1
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 1
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • この総説は下記に紹介されているようにmRNAワクチンの頻回接種後のIgG4の上昇で「免疫寛容」が促進される「かも」といっているだけで↓ https://www.igakuken.or.jp/r-info/covid-19-info182.html 「免疫寛容」の有無に関わらず、実際にはワクチンの発症・重症予防効果は際限なく繰り返し報告済な事に注意が必要です。 ワクチンの頻回接種のオミクロンへの発症予防効果は遅れて行われた幼児のランダム化比較試験でも確認されており↓ https://www.cov19-vaccine.mhlw.go.jp/qa/uploads/0150_221025.pdf オミクロン期の頻回接種の発症・重症予防効果は観察研究のメタ解析でも示され↓ https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00409-1/fulltext 国内でもオミクロン期でも感染研から示され https://medical-tribune.co.jp/news/2023/0519556650/ 長崎大からも示されています https://www3.nhk.or.jp/news/html/20230304/k10013998631000.html

Note Status History

createdAt timestampMillisOfFirstNonNMRStatus firstNonNMRStatus timestampMillisOfCurrentStatus currentStatus timestampMillisOfLatestNonNMRStatus mostRecentNonNMRStatus participantId
2024-03-18 11:16:05 UTC
(1710760565817)
2024-03-18 17:43:09 UTC
(1710783789756)
CURRENTLY_RATED_HELPFUL 2024-03-19 02:27:56 UTC
(1710815276736)
NEEDS_MORE_RATINGS 2024-03-18 17:43:09 UTC
(1710783789756)
CURRENTLY_RATED_HELPFUL

Note Ratings

rated at rated by
2024-03-18 20:32:18 -0500 Rating Details
2024-03-18 19:52:20 -0500 Rating Details
2024-03-18 19:29:17 -0500 Rating Details
2024-03-18 18:53:22 -0500 Rating Details
2024-03-18 18:47:36 -0500 Rating Details
2024-03-18 18:27:31 -0500 Rating Details
2024-03-18 17:26:30 -0500 Rating Details
2024-03-18 16:19:56 -0500 Rating Details
2024-03-18 11:38:16 -0500 Rating Details
2024-03-18 09:48:08 -0500 Rating Details
2024-03-18 09:05:28 -0500 Rating Details
2024-03-18 08:56:48 -0500 Rating Details
2024-03-18 08:18:11 -0500 Rating Details
2024-03-18 08:13:54 -0500 Rating Details
2024-03-18 07:56:44 -0500 Rating Details
2024-03-18 07:50:49 -0500 Rating Details
2024-03-18 07:30:14 -0500 Rating Details
2024-03-18 07:21:21 -0500 Rating Details
2024-03-18 07:03:18 -0500 Rating Details
2024-03-18 07:02:56 -0500 Rating Details
2024-03-18 06:57:44 -0500 Rating Details
2024-03-18 06:57:03 -0500 Rating Details
2024-03-18 06:54:38 -0500 Rating Details
2024-03-18 06:48:33 -0500 Rating Details
2024-03-18 06:35:08 -0500 Rating Details
2024-03-20 08:01:20 -0500 Rating Details
2024-03-19 11:49:21 -0500 Rating Details
2024-03-19 08:25:01 -0500 Rating Details
2024-03-19 03:28:15 -0500 Rating Details
2024-03-18 16:45:49 -0500 Rating Details
2024-03-18 11:52:06 -0500 Rating Details
2024-03-18 10:42:30 -0500 Rating Details
2024-03-18 10:31:38 -0500 Rating Details
2024-03-18 09:32:00 -0500 Rating Details
2024-03-18 08:43:45 -0500 Rating Details
2024-03-18 08:25:38 -0500 Rating Details
2024-03-18 08:13:55 -0500 Rating Details
2024-03-18 08:08:30 -0500 Rating Details
2024-03-18 08:06:34 -0500 Rating Details
2024-03-18 07:38:18 -0500 Rating Details
2024-03-18 07:16:14 -0500 Rating Details
2024-03-18 07:13:40 -0500 Rating Details
2024-03-18 07:11:59 -0500 Rating Details
2024-03-18 07:00:32 -0500 Rating Details
2024-03-18 06:58:15 -0500 Rating Details
2024-03-18 06:58:04 -0500 Rating Details
2024-03-18 06:52:16 -0500 Rating Details
2024-03-18 06:41:21 -0500 Rating Details
2024-03-18 06:31:49 -0500 Rating Details
2024-03-18 21:10:05 -0500 Rating Details
2024-03-18 21:10:00 -0500 Rating Details
2024-03-18 20:33:14 -0500 Rating Details
2024-03-18 19:37:41 -0500 Rating Details
2024-03-18 18:23:32 -0500 Rating Details
2024-03-18 18:15:22 -0500 Rating Details
2024-03-18 17:44:42 -0500 Rating Details
2024-03-18 17:40:30 -0500 Rating Details
2024-03-18 16:11:37 -0500 Rating Details
2024-03-18 10:47:03 -0500 Rating Details
2024-03-18 10:23:07 -0500 Rating Details
2024-03-18 09:57:30 -0500 Rating Details
2024-03-18 09:17:00 -0500 Rating Details
2024-03-18 08:04:19 -0500 Rating Details
2024-03-18 07:33:03 -0500 Rating Details
2024-03-18 07:26:19 -0500 Rating Details
2024-03-18 07:18:13 -0500 Rating Details
2024-03-18 07:14:15 -0500 Rating Details
2024-03-18 07:04:47 -0500 Rating Details
2024-03-18 06:55:25 -0500 Rating Details
2024-03-18 06:52:24 -0500 Rating Details
2024-03-18 06:47:34 -0500 Rating Details
2024-03-18 06:42:28 -0500 Rating Details
2024-03-18 06:41:01 -0500 Rating Details
2024-03-18 06:35:00 -0500 Rating Details